With the new frontier of digital health comes danger

KEY TAKEAWAY: Theranos, led by CEO and founder Elizabeth Holmes, raised more than $700 million on the promise of a revolutionary blood-testing technology that never materialized. The Securities and Exchange Commission just charged Holmes with “massive fraud.”  Yet shouldn’t the investors have done their “due diligence” before investing money into a promise that was too good to be true? Continue reading